7 results about "P53 pathway" patented technology

The invention discloses an application of a targeted ECT2 inhibitor in preparation of a product for treating renal interstitial fibrosis. According to the application, a brand-new and unprecedented molecular pathway which activates a p53 pathway by inhibiting ribosome biogenesis (RiBi) and finally causes renal tubular cell aging and renal fibrosis is revealed and confirmed for the first time, and a solid theoretical basis is provided for precise drugs aiming at the pathway; and a major breakthrough from relevance observation to causality mechanism clarification is realized.

The application discloses application of an alkaloid derivative or a medicinal salt thereof in preparation of a medicine for resisting non-small cell lung cancer cisplatin resistance, and a structure of the alkaloid derivative is as follows: The application finds that compound A45 can induce K48 connection type polyubiquitination of TNKS, and is degraded through a proteasome pathway, triggers a DNA damage response, activates a p53 pathway, and induces autophagic cell death, so that a specific action mechanism is achieved to achieve a treatment effect of resisting non-small cell lung cancer cisplatin resistance. Therefore, the compound A45 can be used as a candidate compound for the non-small cell lung cancer cisplatin resistance, a major treatment dilemma, has important development prospects and clinical application value, and provides a scientific basis and an experimental basis for development of an antitumor effect of other Aaptamine alkaloid derivatives and exploration of a strategy for overcoming the non-small cell lung cancer cisplatin resistance.

The application discloses application of a petroleum ether extract of a root of a roadside green plant in preparation of a drug for treating colorectal cancer by regulating a PI3K / AKT / MDM2 / p53 pathway. In the application, the petroleum ether extract of the root of the roadside green plant for treating colorectal cancer is obtained by petroleum ether reflux extraction of the root of the roadside green plant. Pharmacological experiments show that the petroleum ether extract of the root of the roadside green plant treats colorectal cancer by regulating the PI3K / AKT / MDM2 / p53 signal pathway through down-regulating p-PI3K / PI3K and p-AKT / AKT ratio, up-regulating p-MDM2 and down-regulating p53 level; the extract has an anti-malignant proliferation effect, induces G1 phase arrest by targeting CDK2, up-regulating p21, down-regulating Cyclin E1-CDK2 and Cyclin D1-CDK4; the extract induces HCT-116 cell apoptosis through a mitochondrial pathway by up-regulating Bax / Bcl-2, reducing ΔΨm, releasing Cyt C, activating Caspase-9 / 3 and cleaving PARP; the extract inhibits migration and invasion of HCT-116 cells by targeting MMP9, down-regulating MMP-2, MMP-9 and N-cadherin expression and up-regulating E-cadherin expression. In addition, the extract inhibits growth of a transplanted tumor in a nude mouse transplanted tumor model by inducing apoptosis of transplanted tumor cells.

The present application relates to a kind of heterocyclic compounds and its application, the structure of the heterocyclic compound is as shown in formula (I) or formula (II), it is proved by experiment that the heterocyclic compounds can be degraded CK1 alpha by molecular glue mechanism, thereby affecting p53 pathway, Wnt / β-catenin pathway and ATM pathway etc., can be used for preventing or treating the disease caused by CK1 alpha abnormal high expression, can be used for preparing the drug for treating hematological malignancies and solid tumor, especially for preparing the drug for treating acute myeloid leukemia.

Disclosed herein are chimeric blastocysts, such as chimeric blastocysts derived from a host blastocyst from a first mammalian species and having donor pluripotent stem cells from a second mammalian species, wherein the donor pluripotent stem cells have reduced expression or reduced biological activity of one or more proteins in the TLR / NF-kB signaling pathway or the p53 pathway. Methods of preparing chimeric blastocysts and methods of obtaining mammalian organs and tissues are also provided.

The invention belongs to the technical field of biological medicines, and relates to application of small nucleolus SnoRD89 in preparation of an ovarian cancer targeting drug. The invention discloses that SnoRD89 inhibits the malignant phenotype of ovarian cancer cells by influencing the RPL11 / MDM2 / P53 pathway for the first time. The invention finds a new effective method for targeted regulation and control of apoptosis signal channels, that is, ovarian cancer cell apoptosis is induced through siRNA of targeted SnoRD89, and the method is applied to basic medical research.

The invention provides application of berberrubine in preparation of a medicine for preventing and treating lung cancer. The technical scheme provided by the invention is developed around an MDM2 / p53 pathway, tumor inhibition is realized by inducing cell aging, and the technical scheme is clear in molecular mechanism and definite in intervention target, and has repeatability and verifiability. Compared with traditional radiotherapy and chemotherapy drugs, the technical scheme provided by the invention does not cause acute cell death, and the overall toxicity is relatively low. Meanwhile, according to the technical scheme provided by the invention, the preparation process of the raw material berberrubine is mature, and the berberrubine can be developed into various dosage forms and has a good application prospect.